PL364048A1 - Sposób doboru peptydu - Google Patents

Sposób doboru peptydu

Info

Publication number: PL364048A1
Authority: PL; Poland
Prior art keywords: selection method; peptide; peptide selection; mbp; peptides
Prior art date: 2000-08-21

Application number

PL01364048A

Other languages

English (en)

Other versions

PL217929B1 (pl

Inventor

David Cameron Wraith

Stephen Mark Anderton

Graziella Mazza

Mary Ponsford

Heather Barbara Streeter

Original Assignee

Apitope Technology (Bristol) Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-21

Filing date

2001-08-17

Publication date

2004-12-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL364048(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-21 Priority claimed from GB0020618A external-priority patent/GB0020618D0/en

2001-06-14 Priority claimed from GB0114547A external-priority patent/GB0114547D0/en

2001-08-17 Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited

2004-12-13 Publication of PL364048A1 publication Critical patent/PL364048A1/pl

2014-09-30 Publication of PL217929B1 publication Critical patent/PL217929B1/pl

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
238000010187 selection method Methods 0.000 title 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
102000043129 MHC class I family Human genes 0.000 abstract 1
108091054437 MHC class I family Proteins 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000003614 tolerogenic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Rehabilitation Therapy (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)

PL364048A 2000-08-21 2001-08-17 Sposób wyboru in vitro peptydu przydatnego w zapobieganiu i/lub leczeniu chorób z nadmiernym uczuleniem PL217929B1 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0020618A GB0020618D0 (en)	2000-08-21	2000-08-21	Peptide selection method
GB0114547A GB0114547D0 (en)	2001-06-14	2001-06-14	Peptide selection method
PCT/GB2001/003702 WO2002016410A2 (en)	2000-08-21	2001-08-17	Peptide selection method

Publications (2)

Publication Number	Publication Date
PL364048A1 true PL364048A1 (pl)	2004-12-13
PL217929B1 PL217929B1 (pl)	2014-09-30

Family

ID=26244875

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL395781A PL213585B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL399137A PL215187B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL399138A PL215145B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL364048A PL217929B1 (pl)	2000-08-21	2001-08-17	Sposób wyboru in vitro peptydu przydatnego w zapobieganiu i/lub leczeniu chorób z nadmiernym uczuleniem

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL395781A PL213585B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL399137A PL215187B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL399138A PL215145B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Country Status (25)

Country	Link
US (4)	US20030191063A1 (pl)
EP (3)	EP1918298B1 (pl)
JP (1)	JP5431628B2 (pl)
KR (1)	KR20030062321A (pl)
CN (4)	CN102764425B (pl)
AT (2)	ATE401343T1 (pl)
AU (2)	AU7863701A (pl)
BR (2)	BRPI0113400B1 (pl)
CA (1)	CA2420949C (pl)
CY (3)	CY1108558T1 (pl)
CZ (1)	CZ307202B6 (pl)
DE (2)	DE60134862D1 (pl)
DK (3)	DK1311542T3 (pl)
ES (3)	ES2439899T3 (pl)
HK (1)	HK1052359B (pl)
HU (3)	HU229489B1 (pl)
IL (1)	IL154089A0 (pl)
MX (1)	MXPA03001606A (pl)
NO (2)	NO330535B1 (pl)
NZ (1)	NZ523841A (pl)
PH (1)	PH12013500208B1 (pl)
PL (4)	PL213585B1 (pl)
PT (3)	PT1918298E (pl)
SI (3)	SI1918298T1 (pl)
WO (1)	WO2002016410A2 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102764425B (zh) *	2000-08-21	2015-11-25	阿皮托普技术(布里斯托尔)有限公司	肽选择方法
GB0202399D0 (en) *	2002-02-01	2002-03-20	Univ Bristol	Peptide
PT2016414E (pt) *	2006-05-05	2015-11-24	Opexa Therapeutics	Vacina de células t
GB0710529D0 (en)	2007-06-01	2007-07-11	Circassia Ltd	Vaccine
NZ583362A (en)	2007-08-15	2012-06-29	Circassia Ltd	Peptide with reduced dimer formation
ATE518546T1 (de) *	2007-10-31	2011-08-15	Apitope Technology Bristol Ltd	Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen
GB0723712D0 (en)	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides
ITMI20080508A1 (it) *	2008-03-27	2009-09-28	Istituto Nazionale Di Genetica Molecolare	Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) *	2008-05-13	2009-11-14	Istituto Naz Di Genetica Molecolare Ingm	Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
US9085798B2 (en)	2009-04-30	2015-07-21	Prognosys Biosciences, Inc.	Nucleic acid constructs and methods of use
GB0908515D0 (en) *	2009-05-18	2009-06-24	Apitope Technology Bristol Ltd	Peptide
EP2488196B1 (en)	2009-10-12	2015-12-16	LIFEBio Laboratories LLC	Composition for treatment of multiple sclerosis
RU2448685C2 (ru) *	2009-11-30	2012-04-27	Российская Федерация в лице Министерства промышленности и торговли Российской Федерации	Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
US10787701B2 (en)	2010-04-05	2020-09-29	Prognosys Biosciences, Inc.	Spatially encoded biological assays
WO2011127099A1 (en)	2010-04-05	2011-10-13	Prognosys Biosciences, Inc.	Spatially encoded biological assays
US20190300945A1 (en)	2010-04-05	2019-10-03	Prognosys Biosciences, Inc.	Spatially Encoded Biological Assays
KR200457779Y1 (ko) *	2010-06-23	2012-01-06	이준혁	샤프펜슬
EP2694709B1 (en)	2011-04-08	2016-09-14	Prognosys Biosciences, Inc.	Peptide constructs and assay systems
GB201106254D0 (en)	2011-04-13	2011-05-25	Frisen Jonas	Method and product
PL397623A1 (pl) *	2011-12-30	2013-07-08	Napco S. Ar.L.	Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
EP4592400A3 (en)	2012-10-17	2025-10-29	10x Genomics Sweden AB	Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
EA036483B1 (ru)	2012-11-12	2020-11-16	Эпитоп Интернэшнл Нв	Пептиды, способные индуцировать толерантность к рекомбинантному fviii, содержащая их композиция, их применение и способ лечения гемофилии
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
EP3736573A1 (en) *	2013-03-15	2020-11-11	Prognosys Biosciences, Inc.	Methods for detecting peptide/mhc/tcr binding
CA2916662C (en)	2013-06-25	2022-03-08	Prognosys Biosciences, Inc.	Methods and systems for determining spatial patterns of biological targets in a sample
GB201314052D0 (en) *	2013-08-06	2013-09-18	Apitope Int Nv	Peptides
US10288608B2 (en)	2013-11-08	2019-05-14	Prognosys Biosciences, Inc.	Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko)	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
ES2996234T3 (en)	2014-12-24	2025-02-12	Worg Pharmaceuticals Zhejiang Co Ltd	Composition
EP3901282B1 (en)	2015-04-10	2023-06-28	Spatial Transcriptomics AB	Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP4212547A1 (en)	2015-12-03	2023-07-19	Juno Therapeutics, Inc.	Modified chimeric receptors and related compositions and methods
EP3565823B1 (en)	2017-01-04	2024-05-29	Worg Pharmaceuticals (Zhejiang) Co., Ltd.	S-arrestin peptides and therapeutic uses thereof
US20200046802A1 (en) *	2017-01-04	2020-02-13	Apitope International Nv	Therapeutic method using tolerogenic peptides
GB201700095D0 (en) *	2017-01-04	2017-02-22	Apitope Int Nv	Composition
CN112210010B (zh)	2017-01-06	2023-12-05	优特力克斯有限公司	抗-人4-1bb抗体及其应用
GB201909774D0 (en) *	2019-07-08	2019-08-21	Apitope Tech Bristol Limited	Method
RU2761617C2 (ru) *	2019-10-04	2021-12-13	Жаудат Гафурович Умеров	Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
GB201919222D0 (en)	2019-12-23	2020-02-05	Apitope Int Nv	Composition
EP4081656A1 (en)	2019-12-23	2022-11-02	10X Genomics, Inc.	Compositions and methods for using fixed biological samples in partition-based assays
CN115135984B (zh)	2019-12-23	2025-12-23	10X基因组学有限公司	可逆固定试剂及其使用方法
TR201922305A2 (tr) *	2019-12-30	2021-07-26	T C Erciyes Ueniversitesi	Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11732299B2 (en)	2020-01-21	2023-08-22	10X Genomics, Inc.	Spatial assays with perturbed cells
US11702693B2 (en)	2020-01-21	2023-07-18	10X Genomics, Inc.	Methods for printing cells and generating arrays of barcoded cells
US20210230681A1 (en)	2020-01-24	2021-07-29	10X Genomics, Inc.	Methods for spatial analysis using proximity ligation
US11835462B2 (en)	2020-02-11	2023-12-05	10X Genomics, Inc.	Methods and compositions for partitioning a biological sample
US11926863B1 (en)	2020-02-27	2024-03-12	10X Genomics, Inc.	Solid state single cell method for analyzing fixed biological cells
CA3182369A1 (en)	2020-05-06	2021-07-22	Imcyse Sa	Combination treatment for fumarate-related diseases
EP4414459B1 (en)	2020-05-22	2025-09-03	10X Genomics, Inc.	Simultaneous spatio-temporal measurement of gene expression and cellular activity
US12265079B1 (en)	2020-06-02	2025-04-01	10X Genomics, Inc.	Systems and methods for detecting analytes from captured single biological particles

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1327162C (en)	1987-04-09	1994-02-22	Board Of Trustees Of The Leland Stanford Junior University (The)	Method for prophylactically treating an individual for an autoimmune disease
EP0359783B2 (en)	1987-06-24	2002-04-17	Autoimmune, Inc.	Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) *	1988-06-23	1993-11-09	Anergen, Inc.	MHC conjugates useful in ameliorating autoimmunity
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
US6077509A (en) *	1990-03-30	2000-06-20	Autoimmune, Inc.	Peptide fragments of myelin basic protein
US5593698A (en)	1990-10-31	1997-01-14	Autoimmune, Inc.	Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) *	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en)	1993-01-29	1999-11-23	University Of Pittsburgh	Elution and identification of T cell epitopes from viable cells
HUT76099A (en) *	1994-05-10	1997-06-30	Immulogic Pharma Corp	Compositions and treatment for multiple sclerosis
WO1995031997A1 (en)	1994-05-20	1995-11-30	UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY	Model for testing immunogenicity of peptides
US6379670B1 (en) *	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) *	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) *	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0825870A4 (en) *	1995-04-20	2002-09-25	Brigham & Womens Hospital	MODULATING CYTOKIN PATTERNS FROM HUMAN T-CELL CLONES
JP4108126B2 (ja) *	1996-04-26	2008-06-25	リュクスウニヴェルシテートテレイデン	Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
EP0849275A1 (en) *	1996-09-26	1998-06-24	Rijksuniversiteit te Leiden	Mannosylated peptides
WO1999063945A2 (en)	1998-06-12	1999-12-16	Sloan-Kettering Institute For Cancer Research	Vaccination strategy to prevent and treat cancers
MY129566A (en) *	1999-01-19	2007-04-30	Nestle Sa	A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
CN102764425B (zh)	2000-08-21	2015-11-25	阿皮托普技术(布里斯托尔)有限公司	肽选择方法
GB0202399D0 (en)	2002-02-01	2002-03-20	Univ Bristol	Peptide
US8314290B2 (en)	2004-12-21	2012-11-20	Monsanto Technology Llc	Temporal regulation of gene expression by MicroRNAs
ATE518546T1 (de) *	2007-10-31	2011-08-15	Apitope Technology Bristol Ltd	Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen
GB0723712D0 (en)	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides

2001
- 2001-08-17 CN CN201210156712.3A patent/CN102764425B/zh not_active Expired - Fee Related
- 2001-08-17 HU HU0300814A patent/HU229489B1/hu not_active IP Right Cessation
- 2001-08-17 DK DK01956718T patent/DK1311542T3/da active
- 2001-08-17 AT AT01956718T patent/ATE401343T1/de active
- 2001-08-17 CA CA2420949A patent/CA2420949C/en not_active Expired - Lifetime
- 2001-08-17 KR KR10-2003-7002514A patent/KR20030062321A/ko not_active Ceased
- 2001-08-17 CN CN201210156674.1A patent/CN102784385B/zh not_active Expired - Fee Related
- 2001-08-17 EP EP08002817A patent/EP1918298B1/en not_active Expired - Lifetime
- 2001-08-17 PL PL395781A patent/PL213585B1/pl unknown
- 2001-08-17 AU AU7863701A patent/AU7863701A/xx active Pending
- 2001-08-17 SI SI200130983T patent/SI1918298T1/sl unknown
- 2001-08-17 US US10/362,264 patent/US20030191063A1/en not_active Abandoned
- 2001-08-17 EP EP01956718A patent/EP1311542B1/en not_active Expired - Lifetime
- 2001-08-17 BR BRPI0113400-0A patent/BRPI0113400B1/pt unknown
- 2001-08-17 PL PL399137A patent/PL215187B1/pl unknown
- 2001-08-17 ES ES06014901.0T patent/ES2439899T3/es not_active Expired - Lifetime
- 2001-08-17 CZ CZ2003-512A patent/CZ307202B6/cs not_active IP Right Cessation
- 2001-08-17 EP EP06014901.0A patent/EP1731912B1/en not_active Expired - Lifetime
- 2001-08-17 IL IL15408901A patent/IL154089A0/xx unknown
- 2001-08-17 HK HK03104592.1A patent/HK1052359B/en not_active IP Right Cessation
- 2001-08-17 AU AU2001278637A patent/AU2001278637B2/en not_active Ceased
- 2001-08-17 AT AT08002817T patent/ATE483729T1/de active
- 2001-08-17 NZ NZ523841A patent/NZ523841A/en not_active IP Right Cessation
- 2001-08-17 WO PCT/GB2001/003702 patent/WO2002016410A2/en not_active Ceased
- 2001-08-17 PL PL399138A patent/PL215145B1/pl unknown
- 2001-08-17 CN CN2009101296721A patent/CN101633689B/zh not_active Expired - Fee Related
- 2001-08-17 MX MXPA03001606A patent/MXPA03001606A/es active IP Right Grant
- 2001-08-17 ES ES08002817T patent/ES2353347T3/es not_active Expired - Lifetime
- 2001-08-17 HU HU1300357A patent/HU229377B1/hu not_active IP Right Cessation
- 2001-08-17 PT PT08002817T patent/PT1918298E/pt unknown
- 2001-08-17 SI SI200131032T patent/SI1731912T1/sl unknown
- 2001-08-17 BR BR0113400-0A patent/BR0113400A/pt not_active IP Right Cessation
- 2001-08-17 PT PT01956718T patent/PT1311542E/pt unknown
- 2001-08-17 DE DE60134862T patent/DE60134862D1/de not_active Expired - Lifetime
- 2001-08-17 DE DE60143234T patent/DE60143234D1/de not_active Expired - Lifetime
- 2001-08-17 JP JP2002521505A patent/JP5431628B2/ja not_active Expired - Fee Related
- 2001-08-17 SI SI200130860T patent/SI1311542T1/sl unknown
- 2001-08-17 HU HU1300358A patent/HU230233B1/hu not_active IP Right Cessation
- 2001-08-17 DK DK08002817.8T patent/DK1918298T3/da active
- 2001-08-17 ES ES01956718T patent/ES2310558T3/es not_active Expired - Lifetime
- 2001-08-17 PT PT60149010T patent/PT1731912E/pt unknown
- 2001-08-17 PL PL364048A patent/PL217929B1/pl unknown
- 2001-08-17 CN CNA018176828A patent/CN1469883A/zh active Pending
- 2001-08-17 DK DK06014901.0T patent/DK1731912T3/da active
2003
- 2003-02-19 NO NO20030790A patent/NO330535B1/no not_active IP Right Cessation
2007
- 2007-10-31 US US11/979,224 patent/US8343500B2/en not_active Expired - Fee Related
2008
- 2008-10-13 CY CY20081101132T patent/CY1108558T1/el unknown
2010
- 2010-10-18 NO NO20101441A patent/NO337988B1/no not_active IP Right Cessation
2011
- 2011-01-04 CY CY20111100017T patent/CY1111079T1/el unknown
2012
- 2012-12-06 US US13/706,540 patent/US8961986B2/en not_active Expired - Fee Related
2013
- 2013-01-31 PH PH12013500208A patent/PH12013500208B1/en unknown
- 2013-12-18 CY CY20131101143T patent/CY1114808T1/el unknown
2018
- 2018-03-20 US US15/926,637 patent/US20180311328A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20101441L (no)	2003-04-22
PH12013500208A1 (en)	2015-04-20
EP1918298A3 (en)	2008-05-28
US8343500B2 (en)	2013-01-01
CZ307202B6 (cs)	2018-03-21
EP1731912A3 (en)	2006-12-27
PH12013500208B1 (en)	2015-04-20
HU230233B1 (hu)	2015-10-28
EP1918298B1 (en)	2010-10-06
PT1918298E (pt)	2010-12-09
DK1731912T3 (da)	2014-01-06
ATE483729T1 (de)	2010-10-15
CN102784385A (zh)	2012-11-21
BR0113400A (pt)	2003-07-08
US20130156798A1 (en)	2013-06-20
WO2002016410A3 (en)	2002-09-12
PL399137A1 (pl)	2012-07-30
PL399138A1 (pl)	2012-07-30
NO330535B1 (no)	2011-05-09
DE60134862D1 (de)	2008-08-28
NO20030790L (no)	2003-04-22
CN101633689A (zh)	2010-01-27
US20180311328A1 (en)	2018-11-01
CN102784385B (zh)	2015-11-25
US20030191063A1 (en)	2003-10-09
IL154089A0 (en)	2003-07-31
CN1469883A (zh)	2004-01-21
BRPI0113400B1 (pt)	2018-05-15
MXPA03001606A (es)	2004-11-01
ES2353347T3 (es)	2011-03-01
PT1311542E (pt)	2008-10-03
HK1052359A1 (en)	2003-09-11
HUP0300814A2 (hu)	2003-10-28
ES2439899T3 (es)	2014-01-27
SI1918298T1 (sl)	2011-01-31
NO337988B1 (no)	2016-07-18
CN102764425A (zh)	2012-11-07
CA2420949C (en)	2012-01-03
CY1114808T1 (el)	2016-12-14
EP1731912A2 (en)	2006-12-13
CY1111079T1 (el)	2015-06-11
KR20030062321A (ko)	2003-07-23
PL215145B1 (pl)	2013-10-31
WO2002016410A2 (en)	2002-02-28
PL215187B1 (pl)	2013-11-29
CA2420949A1 (en)	2002-02-28
JP2004506921A (ja)	2004-03-04
DE60143234D1 (de)	2010-11-18
NO20030790D0 (no)	2003-02-19
PL213585B1 (pl)	2013-03-29
ES2310558T3 (es)	2009-01-16
HK1178437A1 (en)	2013-09-13
DK1311542T3 (da)	2008-11-10
EP1918298A2 (en)	2008-05-07
CY1108558T1 (el)	2014-04-09
AU7863701A (en)	2002-03-04
SI1731912T1 (sl)	2014-05-30
HK1178793A1 (en)	2013-09-19
JP5431628B2 (ja)	2014-03-05
HUP0300814A3 (en)	2005-11-28
EP1311542B1 (en)	2008-07-16
US20080200368A1 (en)	2008-08-21
NZ523841A (en)	2004-07-30
DK1918298T3 (da)	2010-11-29
CN102764425B (zh)	2015-11-25
HU229489B1 (hu)	2014-01-28
CN101633689B (zh)	2013-09-04
EP1311542A2 (en)	2003-05-21
HK1052359B (en)	2008-11-14
US8961986B2 (en)	2015-02-24
AU2001278637B2 (en)	2006-05-25
ATE401343T1 (de)	2008-08-15
SI1311542T1 (sl)	2009-02-28
PL217929B1 (pl)	2014-09-30
HU229377B1 (hu)	2013-11-28
PT1731912E (pt)	2013-12-17
EP1731912B1 (en)	2013-09-25

Legal Events

Date	Code	Title	Description
2015-12-31	RECP	Rectifications of patent specification

Publication	Publication Date	Title
AU7863701A (en)	2002-03-04	Peptide selection method
WO1998026747A3 (en)	1998-09-17	Superantigen based methods and compositions for treatment of diseases
CY1110862T1 (el)	2015-06-10	Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
AU2002229510A1 (en)	2002-08-19	Combined use of factor vii polypeptides and factor viii polypeptides
NZ515936A (en)	2004-12-24	Antigenic Neisserial peptides
IS7296A (is)	2004-06-03	Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
EE200000478A (et)	2002-02-15	Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
WO1999057241A3 (en)	2000-01-13	Myelin basic protein peptides and uses thereof
EP0656010B8 (fr)	2001-11-14	Utilisation de peptide reconnu par une réponse immunitaire pour l'obtention de médicaments déstinés à l'induction de la supression immunitaire.
WO2004069208A3 (en)	2005-01-27	Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO1997039020A3 (en)	1998-01-08	Antigenic sequences of a sperm protein and immunocontraceptive methods
WO2004069205A3 (en)	2004-10-28	Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
PT999849E (pt)	2003-01-31	Utilizacao de lbp no tratamento da septicemia
WO2004080387A3 (en)	2009-03-26	Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins